rs2972164 — PPARG

Intronic PPARG variant associated with rate of change in insulin sensitivity over time, independent of adiposity

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG — When Your Fat Regulator Changes Pace Over Time

PPARG11 PPARG
peroxisome proliferator-activated receptor gamma — a nuclear receptor that acts as the master transcriptional switch for adipocyte differentiation and lipid storage governs how your body creates fat cells and regulates their function. It is the molecular target of thiazolidinedione22 thiazolidinediones (TZDs): a class of insulin-sensitizing drugs including pioglitazone and rosiglitazone that work by binding and activating PPARG drugs used in type 2 diabetes treatment, and sits at the intersection of fat metabolism and insulin action.

The rs2972164 variant is an intronic T-to-C substitution within PPARG on chromosome 3. It does not change the PPARG protein sequence directly, but intronic variants in regulatory genes like PPARG can influence pre-mRNA splicing33 pre-mRNA splicing
the process that removes introns and joins exons to make mature messenger RNA; intronic variants near splice signals or regulatory elements can alter which exons are included and how much protein is made, mRNA stability, or the expression levels of specific isoforms. PPARG produces multiple isoforms (PPARG1 and PPARG2) from different promoters; intronic regulatory elements coordinate their relative expression in adipose tissue and liver.

The Mechanism

Unlike the famous Pro12Ala variant (rs1801282), which changes the PPARG protein itself, rs2972164 lies entirely within an intron. Its clinical relevance is therefore as a haplotype tag44 haplotype tag
a variant in strong linkage disequilibrium with a functional variant nearby; it doesn't cause the phenotype directly but reliably marks the region responsible — a marker for a PPARG haplotype block that modulates how insulin sensitivity changes over time. PPARG intron 2, the region surrounding this locus, contains multiple regulatory elements including binding sites for upstream transcription factors and epigenetic modification marks active in adipose tissue. The T allele at rs2972164 marks a haplotype associated with steeper decline in insulin sensitivity55 insulin sensitivity
how effectively cells respond to insulin to clear glucose from the bloodstream; declining insulin sensitivity is the hallmark trajectory toward type 2 diabetes over years.

The T allele is the reference allele at this locus and is the minor allele in European and East Asian populations but the major allele in African populations, reflecting deep ancestral population stratification across PPARG haplotype structure.

The Evidence

The primary evidence for rs2972164 comes from the BetaGene study66 BetaGene study
Black et al. Variation in PPARG is associated with longitudinal change in insulin resistance in Mexican Americans at risk for type 2 diabetes. J Clin Endocrinol Metab, 2015, a family-based longitudinal cohort of 378 Mexican Americans at risk for type 2 diabetes, followed for a mean of 4.6 years. The study genotyped 18 tag SNPs capturing variation across a 156-kb PPARG region. rs2972164 was one of six variants significantly associated with the rate of change in insulin sensitivity (SI) after adjustment for age, sex, and body fat percentage — crucially, the association was independent of changes in adiposity, suggesting the effect operates through insulin sensitivity pathways rather than body composition alone.

Notably, the Pro12Ala variant (rs1801282) — the most studied PPARG SNP — was not significantly associated with longitudinal insulin sensitivity change in this study. This underscores that the PPARG locus contains functional variation beyond Pro12Ala, and that intronic haplotype structure contributes independently to metabolic trajectories.

Earlier work by Wolford et al.77 Wolford et al.
Wolford et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes, 2005 comprehensively sequenced the entire 156-kb PPARG region in 93 Hispanic women with prior gestational diabetes who participated in the TRIPOD prevention trial. That study identified 8 PPARG variants — primarily intronic and 3′-flanking — associated with differential insulin-sensitizing response to troglitazone (ORs 2.0–2.4), confirming that intronic haplotype variation in this gene region has functional pharmacological consequences.

Practical Implications

For TT carriers (two copies of the risk T allele), the key risk is an accelerated trajectory of declining insulin sensitivity over time — not a single elevated baseline risk, but a steeper slope toward insulin resistance. This makes longitudinal monitoring of insulin sensitivity markers particularly valuable, and dietary strategies that support PPARG activity (such as reducing saturated fat intake and including omega-3 fatty acids) are directly mechanistically relevant given PPARG's role as a lipid sensor.

Interactions

rs2972164 lies within the same PPARG haplotype block as several other intronic and exonic variants including rs1175541, rs1151996, rs11128598, and rs3856806 — all of which were associated with longitudinal insulin sensitivity change in the BetaGene study. The known Pro12Ala missense variant (rs1801282) is located in the same gene but represents an independent functional effect (protein sequence change vs. regulatory haplotype). Carriers of both the Pro12Ala Pro/Pro genotype and the rs2972164 TT genotype may have additive insulin sensitivity risk through two distinct PPARG mechanisms.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Haplotype Normal

Common C/C genotype — typical PPARG haplotype with no evidence of accelerated insulin sensitivity decline

The CC genotype represents the PPARG haplotype block that does not carry the T-allele marker associated with steeper insulin sensitivity decline over time. The BetaGene study (Black et al. 2015) found that the six PPARG variants associated with longitudinal insulin sensitivity change — including rs2972164 — tracked together as part of a haplotype structure, and CC homozygotes were the reference group showing stable or typical insulin sensitivity trajectories. There are no ClinVar entries or established clinical findings that assign risk to the CC genotype.

CT One Risk Allele Intermediate

One copy of the T allele — modest association with insulin sensitivity change over time

The T allele at rs2972164 tags a PPARG haplotype block found to be associated with rate of change in insulin sensitivity over time, independent of changes in body fat. The BetaGene study (Black et al. 2015, n=378 Mexican Americans, 4.6 years mean follow-up) found this effect was distinct from the Pro12Ala (rs1801282) variant's effects, indicating an independent regulatory mechanism within PPARG's intronic architecture. As an intronic variant, it likely acts through altered splicing of PPARG isoforms or expression of regulatory elements in the intron 2 region, reducing the gene's adaptive capacity to maintain insulin sensitivity over time. Heterozygous CT carriers have one copy of the risk haplotype and are expected to show an intermediate phenotype.

TT Two Risk Alleles Decreased

Two copies of the T allele — strongest association with accelerated insulin sensitivity decline over time

The TT genotype carries two copies of the PPARG haplotype block tagged by the T allele at rs2972164, associated with accelerated decline in insulin sensitivity (SI) over a mean 4.6-year follow-up, independent of age, sex, and body fat changes. This haplotype-based effect is biologically distinct from the Pro12Ala missense variant (rs1801282), operating through PPARG's intronic regulatory architecture — likely via altered expression of PPARG1 vs. PPARG2 isoforms, disrupted intron 2 regulatory elements, or modified pre-mRNA splicing. PPARG is the molecular target of thiazolidinedione drugs (pioglitazone, rosiglitazone); earlier pharmacogenomics work in the same PPARG 156-kb region found that intronic haplotype variation predicts differential insulin-sensitizing response to TZDs (Wolford et al. 2005). TT carriers with type 2 diabetes may therefore benefit from genotype-informed pharmacotherapy discussions, and those not yet diabetic should monitor insulin sensitivity trajectories closely over time.